


## RESEARCH ARTICLE

# Analysis of circular RNA expression profiles of lung cancer in Xuanwei, China

Yan Wang<sup>1,2,3,4</sup>  | Ling-Jiao Lu<sup>1,2,3,4</sup> | Yong Duan<sup>1,2,3,4</sup> | Xiao Liu<sup>1,2,3,4</sup> | Yue Mao<sup>1,2,3,4</sup> | Yu Chen<sup>1,2,3,4</sup> | Yan-Liang Zhang<sup>1,2,3,4</sup>

<sup>1</sup>Department of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, China

<sup>2</sup>Yunnan Key Laboratory of Laboratory Medicine, Kunming, China

<sup>3</sup>Yunnan Institute of Laboratory Diagnosis, Kunming, China

<sup>4</sup>Innovation Team of Yunnan Provincial Clinical Laboratory and Diagnosis, Kunming, China

## Correspondence

Yan-Liang Zhang, Department of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming, Yunnan Province, China.  
Email: zylyh2007@163.com

## Funding information

"High-level Talents Training Support Program" of Yunnan Province -- Project for Young Top Talents, Training Program for Leaders of Medical Disciplines of Yunnan Provincial Health Commission, Grant/Award Number: D-2018024; Training Program for 100 Young and Middle-aged Academic and Technical Leaders of Kunming Medical University, Grant/Award Number: 60117190460; National Natural Science Foundation of China, Grant/Award Number: 81660388; Applied Basic Research Project of Science and Technology Department of Yunnan Province-Kunming Medical University Union Fund, Grant/Award Number: 2017FE467(-131)

## Abstract

**Background:** Mounting evidence indicates that circular RNAs (circRNAs) could play a pivotal role in cancers. However, due to the lack of sensitive biomarkers, most lung cancer in Xuanwei (LCXW) patients are still diagnosed at an advanced stage accompany with distant metastasis.

**Methods:** According to the stage of LCXW patients and tissue sources, circRNAs microarray detection was carried out in six groups. Considering fold change, raw intensity, the length of circRNAs, and *P*-value, we selected eight circRNAs for further study. A total of 50 paired LCXW tissues were carried out real-time quantitative polymerase chain reaction (RT-qPCR) in order to extended sample size to verify the expression of these circRNAs.

**Results:** We designed 13 617 human circRNA probes for the human circular RNA microarray, detected 10 819 circRNA in six groups of samples; 537 circRNAs were differentially expressed consistently in every stage. Through RT-qPCR, we selected 8 circRNAs, three of which were upregulated (hsa\_circ\_0005927, hsa\_circ\_0069397 and hsa\_circ\_0000937) and five were downregulated (hsa\_circ\_0001936, hsa\_circ\_0005255, hsa\_circRNA\_406010, hsa\_circ\_0007064, hsa\_circ\_0000907) in tumor tissues, only hsa\_circ\_0001936 showed the opposite expression between microarray and RT-qPCR, others were consistent. Additionally, hsa\_circ\_0005927 and hsa\_circ\_0001936 were significantly correlated with tumor size, and hsa\_circRNA\_406010 was related to the prognosis of LCXW patients.

**Conclusion:** Together, these results suggest that hsa\_circ\_0005927, hsa\_circ\_0001936, and hsa\_circRNA\_406010 may serve as the novel potential biomarkers for LCXW. Moreover, these results may provide a new insight for the pathogenesis of LCXW.

## KEYWORDS

biomarker, circRNA microarray, circular RNA, LCXW, microRNA

Yan Wang and Ling-Jiao Lu contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. *Journal of Clinical Laboratory Analysis* Published by Wiley Periodicals LLC.

## 1 | INTRODUCTION

Lung cancer is the most frequent cause of cancer-related death worldwide, while lung cancer in Xuanwei (LCXW) is one of the most deadly types of lung cancers in China, and the prognosis of LCXW remains poor.<sup>1</sup> Even though current advances in the chemotherapy and molecular targeting therapy for LCXW, the overall 5-year survival rate for the disease is less than 15% due to the limited therapeutic options, tumor metastasis, and recurrence.<sup>2,3</sup> Undoubtedly, a better understanding of the carcinogenesis is critical for the advance of diagnostic markers and aid novel effective therapies for LCXW patients.

In Xuanwei, located on the southwestern border of China, the morbidity and mortality of lung cancer are higher than the other regions of China. According to a survey in 2018, the male mortality rate in LCXW patients was 98.10/105, and the female mortality rate was 83.28/105.<sup>4</sup> Besides, LCXW possesses five unique epidemiological characteristics compared to lung cancer in other regions: related to burning coal rather than smoking; the main histological type is adenocarcinoma; the female is more likely suffered; farmers are more susceptible to lung cancer than urban residents; family aggregation phenomenon between the lung cancer patients. However, the researches were mainly on its epidemiology at present; the explanation for the molecular pathogenesis of high morbidity and high mortality of LCXW is still not fully understood. Therefore, it is urgent to find effective molecular biomarker for LCXW.

CircRNAs are classified as a new kind of RNA that is widely expressed in the eukaryotic cells.<sup>5,6</sup> CircRNAs are conservative between species and specifically expressed according to organs and time.<sup>7</sup> Most of the circRNAs are generated by the splicing of protein-encoding gene, formed the covalently closed circular structures, which made circRNAs have an ability to resist Ribonuclease R,<sup>8</sup> so it is more stable than linear RNA. Increasing studies have shown that circRNAs are pervasively involved in many biological processes, including cellular development, differentiation, apoptosis, inflammation, autophagy, and cancers. Also, an emerging paradigm of the aberrant circRNAs has been found to participate in cancers development and progression. It is also found that circRNAs participate in the translation, such as regulate parental gene expression,<sup>9</sup> paly cis-regulate function,<sup>10</sup> and regulation of alternative splicing.<sup>11</sup> It indicated circRNAs regulate gene expression at a different level of the transcript. For example, circRNA hsa\_circ\_0047905, hsa\_circ\_0138960, and has-circRNA7690-15 may play a role in the formation of gastric cancer.<sup>12</sup> CircRNA hsa\_circ\_0001785 may have a certain value for the diagnosis of breast cancer.<sup>13</sup> Other reports also indicated circRNAs play a critical role in the development of lung adenocarcinoma,<sup>14</sup> colorectal cancer,<sup>15</sup> liver cancer,<sup>16</sup> et al However, the roles that circRNAs in LCXW remain unclear.

In this study, we investigated the expression profile of circRNAs of LCXW patients by employing circular RNA microarray, and there were many differentially expressed circRNAs between tumor tissues and adjacent normal tissues of LCXW. And, we selected eight

circRNAs (hsa\_circ\_0005927, hsa\_circ\_0069397, hsa\_circ\_0001936, hsa\_circ\_0005255, hsa\_circ\_0000937, hsa\_circ\_0007064, hsa\_circ\_0000907, hsa\_circRNA\_406010) as candidate circRNAs according to some criteria for further study. Also, we identified hsa\_circ\_0005927, hsa\_circ\_0001936, and hsa\_circRNA\_406010 may serve as novel potential biomarkers for LCXW. Taken together, the findings may provide new insights into the critical role of the circRNAs in LCXW tumorigenesis.

## 2 | MATERIALS AND METHODS

### 2.1 | Patients and tissues

The LCXW patients enrolled met the following criteria: (a) the patient came from Xuanwei District of Yunnan and lived in this area for more than 15 years; (b) pathological diagnosis belongs to lung cancer; (c) excluding patient who suffered radiotherapy, chemotherapy or immunotherapy before operation; (d) excluding patient with immune system diseases, chronic consumptive diseases or infectious diseases; (e) excluding patient with other malignant tumors. A total of 26 patients (stage I: 10/26; stage II: 9/26; stage III: 7/26) were available for the circRNA microarray. The detection of circRNA microarray was carried out in six groups according to the stage of LCXW patients and tissue sources. For each group of samples, a sample labeled A which instead of LCXW tissues was mixed to cross a dot matrix; a sample labeled P which instead of adjacent normal lung tissues from LCXW patients was mixed to hybridize a dot matrix. Also, 50 paired tissues from LCXW patients were carried out RT-qPCR to extended sample size to verify the expression of circRNAs. All of the patients' clinical information was recorded in detail. All samples including lung cancer tissues and their paired adjacent normal lung tissues were collected from patients who had received surgical treatment at the Thoracic Surgery Department of the First Affiliated Hospital of Kunming Medical University or Xuanwei Yunfeng hospital between September 2011 and September 2017. The pathological diagnosis and the stage of LCXW are obtained by professional pathologists. All the tissue samples were collected, immediately snap-frozen in liquid nitrogen, and stored at  $-80^{\circ}\text{C}$  until RNA extraction.

The use of all tissue blocks for this study was approved by the Institutional Ethics Review Board of Kunming Medical University (Kunming, Yunnan, PR China). Informed consent was obtained from all patients.

### 2.2 | Total RNA isolation and quality control

The total RNA was extracted from tissues with TRIzol reagent (Invitrogen), according to the manufacturers' protocol. The purity and concentration of RNA were determined by OD260 and OD280 using a NanoDrop ND-1000 (Thermo Fisher Scientific). The integrity of RNA was assessed by electrophoresis on a denaturing agarose gel.

**TABLE 1** The PCR primers for related gene

Gene name		Primer sequences	Size (bp)
hsa_circRNA_104600	Forward	5'-TGAATTTGGAGGTTCTATCTACCAG-3'	162
	Reverse	5'-CCTTCAATTTCCCACTCTTCTTT-3'	
hsa_circRNA_069397	Forward	5'-TATCTCCCTATGCCTGCTTTTA-3'	165
	Reverse	5'-TCTACTGGCTTTTCTCTATCA-3'	
hsa_circRNA_105013	Forward	5'-TTCTTCCAGGTGATGGTGAGGT-3'	60
	Reverse	5'-CTTGGTCATTGGTTTGCTGC-3'	
hsa_circRNA_406010	Forward	5'-TGCTTTGTAGTGTGTATCTGC-3'	150
	Reverse	5'-TAACTGTGTGTATCCTGAGTT-3'	
HECW2	Forward	5'-CCTGTTGAGAATGAGGAAGCCT-3'	193
	Reverse	5'-GCTGATCTACCTTTGAGAGCC-3'	
$\beta$ -actin (H)	Forward	5'-GTGGCCGAGGACTTTGATTG-3'	73
	Reverse	5'-CCTGTAACAACGCATCTCATATT-3'	

### 2.3 | CircRNAs labeling and hybridization

Sample labeling and array hybridization were performed according to the manufacturer's protocol (Arraystar Inc). Briefly, total RNAs were digested with Rnase R (Epicentre, Inc) to remove linear RNAs and enrich circular RNAs (circRNAs). Then, the enriched circRNAs were amplified and transcribed into fluorescent cRNA utilizing a random priming method (Arraystar Super RNA Labeling Kit; Arraystar). The labeled cRNAs were purified by RNeasy Mini Kit (Qiagen). The concentration and specific activity of the labeled cRNAs (pmol Cy3/ $\mu$ g cRNA) were measured by NanoDrop ND-1000. 1  $\mu$ g of each labeled cRNA was fragmented by adding 5  $\mu$ L 10 $\times$  Blocking Agent and 1  $\mu$ L of 25 $\times$  Fragmentation Buffer and then heated the mixture at 60°C for 30 minutes. Finally, 25  $\mu$ L 2 $\times$  Hybridization buffer was added to dilute the labeled cRNA. 50  $\mu$ L of hybridisation solution was dispensed into the gasket slide and assembled to the circRNA expression microarray slide. The slides were incubated for 17 hours at 65°C in an Agilent Hybridization Oven. The hybridized arrays were washed, fixed, and scanned using the Agilent Scanner G2505C.

### 2.4 | Data collection and analysis of circRNA microarray

Scanned images were imported into Agilent Feature Extraction software for raw data extraction. Quantile normalization of raw data and subsequent data processing were performed using the R software limma package (Kangcheng Bio-tech). After quantile normalization of the raw data, low-intensity filtering was performed, and the circRNAs that at least three out of six samples have flags in "P" or "M" ("All Targets Value") were retained for further analyses. When comparing two groups of profile differences (such as disease vs control), the "fold change" (ie, the ratio of the group averages) between the groups for each circRNA is computed. The statistical significance of

the difference may be conveniently estimated by *t* test. circRNAs were having fold changes  $\geq 2$  and *P*-values  $< .05$  are selected as the significantly differentially expressed.

### 2.5 | Annotation for circRNA/miRNA interaction


The circRNA/miRNA interaction was predicted with Arraystar's homemade miRNA target prediction software based on TargetScan<sup>17</sup> and miRanda.<sup>18</sup> The five putative target miRNAs were identified from the above analysis. The putative target genes of these miRNAs were identified by Targetscan (TargetScan <http://www.targetscan.org>). Moreover, the differentially expressed circRNAs within all the comparisons were annotated in detail with the circRNA/miRNA interaction information.

### 2.6 | Filter valuable circRNA that potentially related to LCXW

To find valuable circRNAs for further study, we conducted five steps to filter circRNAs, which differentially expressed between tumor tissues and adjacent normal tissues at different stage: (a) Sort from the largest to smallest according to the fold change ( $FC \geq 2$ ); (b) The group raw intensity of all tested samples were rather than 200 (including 200); (c) CircRNAs length at 200-2000 bp; (d) *P*-value less than .05.

### 2.7 | Synthesis of cDNA and RT-qPCR

Total RNA of tissues was extracted using TRIzol (Invitrogen) and RNA/DNA mini Kit (QIAGEN) according to the manufacturer's protocol. Reverse transcription was carried out with PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa) according to the



**FIGURE 1** CircRNA microarray expression data between the LCXW tissues and paired adjacent normal tissues. A, Box plot showed the distributions of circRNAs in six groups (“A” for LCXW tissues and “P” for paired adjacent normal tissues) and the distributions of log<sub>2</sub> ratios among samples were nearly the same after normalization. B, Volcano plots were constructed using fold-change values and *P*-values (“A” for LCXW tissues and “P” for paired adjacent normal tissues). The vertical lines correspond to 2.0-fold up- and downregulation between the LCXW tissues and paired adjacent normal tissues (A vs P), and the horizontal line represents a *P*-value. The red point in the plot represents the differentially expressed circRNAs with statistical significance

manufacturer’s instructions. The cDNA was amplified by All-in-One™ qPCR Mix (GeneCopoeia, America) according to the manufacturer’s instructions in a SLAN-96P system. The primers were designed by Primer 3.0 and primer sequence of each circRNA and β-actin in this study were listed (Table 1). The conditions of amplification for hsa\_circ\_0005927 and hsa\_circ\_0069397: one cycle at 95°C for 10 minutes, 40 cycles at 95°C for 10 seconds followed by 61°C for 60 seconds; for hsa\_circ\_0001936: one cycle at 95°C for 10 minutes, 35 cycles at 95°C for 10 seconds followed by 64°C for 55 seconds; for hsa\_circRNA\_406010: one cycle at 95°C for 10 minutes, 40 cycles at 95°C for 10 seconds followed by 60°C for 45 seconds; for HECW2: one cycle at 95°C for 10 minutes, 40 cycles at 95°C for 10 seconds followed by 67°C for 45 seconds. Sequencing was applied to validate whether the products of qPCR were our target products. β-actin served as internal control.

## 2.8 | Statistical analysis

RT-qPCR results were analyzed and visualized by GraphPad Prism 5.0 (GraphPad Software). Wilcoxon signal rank test was applied to compare the expression level of selected circRNAs between

XWLC tissue group and adjacent normal tissue group, and a *P*-value < .05 was considered statistically significant. Chi-square test was also applied to determine correlations between expression levels of circRNAs and various clinicopathological parameters of XWLC. Kaplan-Meier survival analysis was used to evaluate the relationship between circRNA expression and prognosis of LCXW.

## 3 | RESULTS

### 3.1 | Circular RNA microarray profile of lung cancer in Xuanwei

Total RNA was extracted from LCXW patients as previously described. First, microarray was performed to design 13 617 human circRNA probes, and 10 819 circRNA were detected in six groups of samples. As shown in Figure 1A, the results of six groups of samples have good uniformity. Next, we screened differentially expressed circRNA and drew the volcanic map, the red region represents circRNA, and the difference ratio is more than two times (Figure 1B,  $P \leq .05$ ).

### 3.2 | The differential expression of circRNAs

The fold changes of all differentially expressed circRNAs were more than 2.0. The differentially expressed identified circRNAs of upregulated and downregulated from I to III stages showed a gradually decreasing trend (Table 2). At each stage, the numbers of downregulated circRNAs were more than the upregulated circRNAs. 537 circRNAs were expressed consistently in all stages (Figure 2), including 143 upregulated circRNAs and 394 downregulated circRNAs.

### 3.3 | Analyses of the candidate circRNA

In order to find valuable circRNAs for further study, we conducted five steps to filter circRNAs which differentially expressed. Common circRNAs: differentially expressed in every stage, we selected hsa\_circ\_0005927, hsa\_circ\_0069397, hsa\_circ\_0001936, hsa\_circ\_0005255, and hsa\_circRNA\_406010 for further verification. The circRNAs of up and down from I to III stage gradually decreased: for specifically differentially expressed circRNAs at I stage, we selected hsa\_circ\_0000937, hsa\_circ\_0007064 for further study; For III stage, only hsa\_circ\_0000907 satisfied the criteria as previously described. The information of these circRNAs was listed in Table 3.

### 3.4 | Verification of 8 circRNAs expression

Initially, eight circRNAs were selected for validation, including three upregulated circRNAs (hsa\_circ\_0005927, hsa\_circ\_0069397, hsa\_circRNA\_0000937) and five downregulated circRNAs (hsa\_circ\_0001936, hsa\_circ\_0005255, hsa\_circ\_0007064, hsa\_circ\_0000907, hsa\_circRNA\_406010). However, after trying various primers, hsa\_circ\_0005255, hsa\_circRNA\_0000937, hsa\_circ\_0007064, and hsa\_circ\_0000907 cannot be amplified. Moreover, hsa\_circ\_0005927, hsa\_circ\_0001936, and hsa\_circRNA\_406010 showed statistically significant (Figure 3A-E), and only hsa\_circ\_0001936 showed the opposite expression between microarray and qRT-PCR. The characteristics of successfully validated circRNAs were shown in Table 4. Because some studies had shown intronic circRNA might regulate their parental gene, we selected intronic circRNA—hsa\_circ\_406010 for investigating its corresponding linear mRNA HECW2 in 37 pairs of XWLC tissues (Figure 3F), the qRT-PCR result showed there was no correlation between the expression of hsa\_circ\_406010 and HECW2 (Figure 3G), but HECW2 was significantly downregulated which shared the same tendency with hsa\_circ\_406010 in LCXW.

**TABLE 2** The differentially expressed circRNAs from I to III stage in XWLC


IA_vs_IP		IIA_vs_IIP		IIIA_vs_IIIP	
Up	Down	Up	Down	Up	Down
717	1055	612	806	183	455

### 3.5 | Effect of dysregulated circRNA on patients' survival

We collected the clinicopathological data of 50 LCXW patients. After statistical analysis, we found upregulated hsa\_circ\_0005927 and hsa\_circ\_0001936 were significantly associated with tumor size (Table 5). Survival curves showed that the prognosis of LCXW patients with downregulated hsa\_circRNA\_406010 was poor (Figure 4).

### 3.6 | CircRNA-targeted miRNA prediction and annotation

Recent evidence has demonstrated that circRNAs play a crucial role in fine-tuning the level of miRNA mediated regulation of gene expression by sequestering the miRNAs. Their interaction with disease associated miRNAs indicates that circRNAs are important for disease regulation.<sup>19-21</sup> In order to find the potential miRNA target, the hsa\_circ\_0005927/miRNA and hsa\_circ\_0001936/miRNA interaction were predicted with Arraystar's homemade miRNA target prediction software based on TargetScan and miRanda. The five miRNA targets of hsa\_circ\_0005927, hsa\_circ\_0001936, and hsa\_circRNA\_406010 were equally potential (Table 6). Studies have indicated that miR-548c-3p could suppress cell proliferation in glioma and osteosarcoma.<sup>22,23</sup> A growing number of evidence suggested that miR-592 was involved in tumor initiation and development in several types of human cancers including human non-small cell lung cancer (NSCLC),<sup>24</sup> glioma,<sup>25</sup> et al MiR-486-5p was downregulated in lung cancer<sup>26</sup> and gastric cancer.<sup>27</sup> MiR-135a-5p represses proliferation of head and neck squamous cell carcinoma by targeting



**FIGURE 2** Venn diagram of differentially expressed circRNAs at different stage in LCXW. The green cycle showed the differential expressed circRNAs at stage I, the red cycle showed the differential expressed circRNAs at stage II, and the blue cycle showed the differential expressed circRNAs in stage III

TABLE 3 Eight candidate circular RNA

CircRNA name	Alias	Regulation	Fold change	Length (bp)	Type	P-value	Differentially expressed at
hsa_circRNA_104600	hsa_circ_0005927	Up	9.6217641	379	exonic	.01109507271	Every stage
hsa_circRNA_069397	hsa_circ_0069397	Up	7.342784	1646	exonic	.01439756458	Every stage
hsa_circRNA_105013	hsa_circ_0001936	Down	-10.4451322	676	exonic	.02822017592	Every stage
hsa_circRNA_005255	hsa_circ_0005255	Down	-8.3910993	311	exonic	.01946425299	Every stage
hsa_circRNA_406010		Down	-7.0959405	1242	intronic		Every stage
hsa_circRNA_000937	hsa_circ_0000937	Up	7.5472908	1059	exonic		I stage
hsa_circRNA_102151	hsa_circ_0007064	Down	-4.05287	356	exonic		I stage
hsa_circRNA_102471	hsa_circ_0000907	Down	-2.5308133	898	exonic		III stage


HOXA10.<sup>28</sup> MiR-619-5p was upregulated in prostatic cancer.<sup>29</sup> Thus, we may believe hsa\_circ\_0005927, hsa\_circ\_0001936, and hsa\_circRNA\_406010 might have a certain function in the development of LCXW via absorbing their predicted miRNAs.

## 4 | DISCUSSION

In this study, we discovered 537 differentially expressed circRNAs in every stage of LCXW, including 143 upregulated and 394 downregulated. Moreover, it indicated that differentially expressed circRNAs might be related to pathogenesis and development of LCXW. Through

RT-qPCR, we identified hsa\_circ\_0005927 and hsa\_circ\_0001936 were significantly upregulated and hsa\_circRNA\_406010 was statistically downregulated in tumor tissues. Besides, upregulated hsa\_circ\_0005927 and hsa\_circ\_0001936 were significantly associated with tumor size, and downregulated hsa\_circRNA\_406010 was related to the prognosis of LCXW patients.

Recently, Huang et al<sup>30</sup> analyzed three paired gastric cancer tissues and paired adjacent normal tissues by utilizing circRNA microarray and RT-qPCR, and they found that hsa\_circ\_0005927 is significantly downregulated in gastric cancer tissues. However, in this study, both microarray and RT-qPCR result showed hsa\_circ\_0005927 was upregulated in LCXW, and it is illustrated



**FIGURE 3** A~D, The relative expression levels of hsa\_circRNA\_104600, hsa\_circRNA\_069397, hsa\_circRNA\_105013, and hsa\_circRNA\_406010 were examined in 50 paired tissue samples by RT-qPCR; E, Comparison of circRNA expression levels between RT-qPCR results and microarray. Candidate circRNAs of differential expression in microarray were validated by RT-qPCR in LCXW samples. The heights of the columns represent the mean fold changes of expression level between LCXW and normal group. Asterisks indicate significant differences (\* means  $P \leq .05$ ; \*\* means  $P \leq .01$ ; \*\*\* means  $P \leq .005$ ; \*\*\*\* means  $P \leq .001$ ). F, The relative expression levels of mRNA HECW2 were examined in 37 paired tissue samples by RT-qPCR; mRNA HECW2 was significantly downregulated in LCXW tissues. G, The relative expression levels of mRNA HECW2 and hsa\_circRNA\_406010 in 37 paired LCXW samples have no correlation

**TABLE 4** Four differently expressed circRNAs for qRT-PCR validation

CircRNA name	IA_vs_IP (raw intensity)		IIA_vs_IIP (raw intensity)		IIIA_vs_IIIP (raw intensity)		Regulation	Length	Fold change (microarray)	Type
	A	P	A	P	A	P				
hsa_circRNA_104600	2970	428	5691	458.5	1787	268	Up	379	9.6217641	Exonic
hsa_circRNA_069397	2074.5	417	3744.5	353	1198	227	Up	1646	7.342784	Exonic
hsa_circRNA_105013	339	5288	361	2671.5	604	1284.5	Down	676	-10.4451322	Exonic
hsa_circRNA_406010	322.5	3478	1452	2871	629	849	Down	1242	-7.0959405	Intronic


dysregulation of hsa\_circ\_0005927 happened in the progression of tumor. Besides, this study also found that dysregulated hsa\_circ\_0005927 was related to the tumor size, suggesting that the expression of hsa\_circ\_0005927 may be related to the growth and proliferation of LCXW. What is more, the downregulated of predicted miRNA of hsa\_circ\_0005927 is also associated with progression of some tumors.<sup>22-25,31</sup> It is worth noting that predicted miR-592 function as a tumor suppressor in NSCLC by targeting SOX9,<sup>25</sup> SOX9 is significantly upregulated in NSCLC and NSCLC cell lines<sup>32</sup> and promote the proliferation of lung cancer cells,<sup>33</sup> and SOX9 also mediates Notch1-induced epithelial mesenchymal transformations (EMT) in lung adenocarcinoma.<sup>34</sup> Therefore, all above suggested hsa\_circ\_0005927 may serve as a potential biomarker for LCXW.

RT-qPCR showed that hsa\_circ\_0001936 was significantly downregulated in LCXW, which was not consistent with the microarray result. The possible reason was that this study employed a method of mix samples when hybridized microarray. However, this method may contribute to losing personality characteristics of the individual sample; it was a benefit for acquiring a general trend. However, RT-qPCR was a further verification for microarray, and the result from RT-qPCR was more credible. There is no report about hsa\_circ\_0001936 with disease so far. However, this study identified the dysregulated hsa\_circ\_0001936 was associated with tumor size also. In addition, while among the hsa\_circ\_0001936 putative miRNA, miR-486-5p was downregulated and contributes to tumor progression by targeting protumorigenic ARHGAP5 in lung cancer.<sup>26</sup>

**TABLE 5** Correlation between circRNA and clinicopathological features

Parameter	Number	Percentage (%)	P		
			hsa_circRNA_104600	hsa_circRNA_105013	hsa_circRNA_406010
Total	50				
Sex					
Male	26	52	.4186	.9442	.5136
Female	24	48			
Age (y)					
≤50	27	54	.4831	.3091	.0567
≥51	23	46			
Smoking history					
Yes	22	44	.1035	.1660	.8326
No	28	56			
Pathologic stage					
I	12	24	.4609	.5018	.2474
II	26	52			
III	12	24			
Lymph node metastasis					
Yes	28	56	.2952	.8326	.8326
No	22	44			
Tumor size (cm)					
≤3.0	18	36	.0145*	.0373*	.7067
>3.0	32	64			

\*Means  $P \leq .05$ .



**FIGURE 4** Survival curves showed that downregulated hsa\_circRNA\_406010 was related to poor prognosis of LCXW

**TABLE 6** Five predicted miRNAs of hsa\_circRNA\_104600, hsa\_circRNA\_105013, and hsa\_circRNA\_406010

CircRNA name	Fold change	MRE1	MRE2	MRE3	MRE4	MRE5
hsa_circRNA_104600	9.6217641	hsa-miR-609	hsa-miR-758-5p	hsa-miR-548c-3p	hsa-miR-592	hsa-miR-452-3p
hsa_circRNA_105013	-10.4451322	hsa-miR-141-5p	hsa-miR-486-5p	hsa-miR-578	hsa-miR-135a-5p	hsa-miR-135b-5p
hsa_circRNA_406010	-7.0959405	hsa-miR-4778-5p	hsa-miR-5690	hsa-miR-1200	hsa-miR-619-5p	hsa-miR-212-5p

Therefore, hsa\_circ\_0001936 may also serve as a potential biomarker for LCXW.

Hsa\_circRNA\_406010 was statistically downregulated in LCXW, and there are no reports showed hsa\_circRNA\_406010 is related to diseases. According to literature, intron circRNAs can directly regulate the expression of the host gene, due to hsa\_circRNA\_406010 belongs to intron circRNA, and expression of its host gene is also studied. It was found that mRNA HECW2 was downregulated in 37 paired LCXW tissues, although the expression trend was the same with hsa\_circRNA\_406010, there was no correlation between HECW2 and hsa\_circRNA\_406010. Due to the limited number of samples, the direct role of hsa\_circRNA\_406010 and mRNA HECW2 still needs further experimental confirmation. Besides, this study also found that the prognosis of LCXW patient with low expression of hsa\_circRNA\_406010 was poor. Additionally, among the hsa\_circRNA\_406010 putative miRNA, miR-619-5p was upregulated in prostatic cancer.<sup>29</sup> Thus, hsa\_circRNA\_406010 may be a potential biomarker for LCXW and even serve as a biomarker for evaluating the prognosis of LCXW.

We selected eight circRNAs as the candidates for RT-qPCR verification; however, the successful verification rate of circRNA was not ideal because of after trying various primers, and half of candidates cannot be amplified. There are two reasons may be responsible for: firstly, variable splicing diversity in circRNAs; secondly, although the total amount of circRNAs could reach 10 times than linear RNA, some circRNA at a very low expression, which leads to amplify difficultly. In addition to appealing for two reasons, it may be

due to the quality and specificity of the primers, or the quality and specificity of the enzymes involved in the reaction, or it may be due to the PCR cycling conditions set in the experiment. Huang et al<sup>30</sup> have mentioned in their study of circRNAs, the reason for failure to design circRNA primers may cause by the pretty low expression of circRNA.

In summary, this study reveals the circRNAs expression profile in LCXW. hsa\_circ\_0005927, hsa\_circ\_0001936, and hsa\_circRNA\_406010 were differentially expressed in LCXW, and their predicted miRNAs took part in regulating the progression of many cancers, for example, dysregulated of these miRNAs were associated with tumor size or related to poor prognosis of LCXW(The predicted miRNA of hsa\_circ\_0005927 include hsa-miR-609, hsa-miR-758-5p, hsa-miR-548c-3p, hsa-miR-592, and hsa-miR-452-3p; The predicted miRNA of hsa\_circ\_0001936 includes hsa-miR-141-5p, hsa-miR-486-5p, hsa-miR-578, hsa-miR-135a-5p, and hsa-miR-135b-5p; The predicted miRNA of hsa\_circRNA\_406010 includes hsa-miR-4778-5p, hsa-miR-5690, hsa-miR-1200, hsa-miR-619-5p, and hsa-miR-212-5p). Thus, we may believe hsa\_circ\_0005927, hsa\_circ\_0001936, and hsa\_circRNA\_406010 may serve as potential biomarkers and estimate the prognosis for LCXW. However, the specific mechanisms including target gene of downstream of these circRNAs need further investigate.

#### ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (81660388), Applied Basic Research



Project of Science and Technology Department of Yunnan Province-Kunming Medical University Union Fund (2017FE467-(131)), "High-level Talents Training Support Program" of Yunnan Province—Project for Young Top Talents, Training Program for Leaders of Medical Disciplines of Yunnan Provincial Health Commission (D-2018024), and Training Program for 100 Young and Middle-aged Academic and Technical Leaders of Kunming Medical University (60117190460). We thank all the participants in the study.

## CONFLICT OF INTEREST

The authors declare no conflicts of interest.

## ORCID

Yan Wang  <https://orcid.org/0000-0001-5178-2020>

## REFERENCES

- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115-132.
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65(2):87-108.
- Shi Y, Sun Y, Ding C, et al. China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). *Ann Trans Med*. 2015;3(18):260.
- Wu H, Meng S, Xu Q, et al. Gene expression profiling of lung adenocarcinoma in Xuanwei, China. *Eur J Cancer Prev*. 2016;25(6):508-517.
- Arnberg AC, Ommen GJBV, Grivell LA, et al. Some yeast mitochondrial RNAs are circular. *Cell*. 1980;19(2):313-319.
- Cocquerelle C, Mascrez B, Héтуin D, et al. Mis-splicing yields circular RNA molecules. *FASEB J*. 1993;7(1):155-160.
- Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA*. 2013;19(2):141-157.
- Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant RNAs. *Int J Mol Sci*. 2014;15(6):9331-9342.
- Zhang XO, Wang HB, Zhang Y, et al. Complementary sequence-mediated exon circularization. *Cell*. 2014;159(1):134-147.
- Zhang Y, Zhang XO, Chen T, et al. Circular intronic long noncoding RNAs. *Mol Cell*. 2013;51(6):792-806.
- Lasda E, Parker R. Circular RNAs: diversity of form and function. *RNA*. 2014;20(12):1829-1842.
- Lai ZY, Yang Y, Yan Y, et al. Analysis of co-expression networks for circular RNAs and mRNAs reveals that circular RNAs hsa\_circ\_0047905, hsa\_circ\_0138960 and has-circRNA7690-15 are candidate oncogenes in gastric cancer. *Cell Cycle*. 2017;16(23):2301-2311.
- Yin WB, Yan MG, Fang X, et al. Circulating circular RNA hsa\_circ\_0001785 acts as a diagnostic biomarker for breast cancer detection. *Clin Chim Acta*. 2018;487:363-368.
- Zhu X, Wang X, Wei S, et al. hsa\_circ\_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma. *FEBS J*. 2017;284(14):2170-2182.
- Wang X, Zhang Y, Huang L, et al. Decreased expression of hsa\_circ\_001988 in colorectal cancer and its clinical significances. *Int J Clin Exp Pathol*. 2015;8(12):16020-16025.
- Qin M, Liu G, Huo X, et al. Hsa\_circ\_0001649: a circular RNA and potential novel biomarker for hepatocellular carcinoma. *Cancer Biomarkers*. 2016;16(1):161-179.
- Enright A, John B, Gaul U, et al. MicroRNA targets in drosophila. *Genome Biol*. 2003;5:R1.
- Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. *Nat Rev Genet*. 2012;13:271-282.
- Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. *Nature*. 2013;495(7441):384-388.
- Ghosal S, Das S, Sen R, et al. Circ2Traits: a comprehensive database for circular RNA potentially associated with disease and traits. *Front Genet*. 2013;4(283):283.
- Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. *Cancer Res*. 2013;73(18):5609-5612.
- Lu J, Zhang M, Yang X, et al. MicroRNA-548c-3p inhibits T98G glioma cell proliferation and migration by downregulating c-Myb. *Oncol Lett*. 2017;13(5):3866-3872.
- Luo Z, Li D, Luo X, et al. Decreased expression of miR-548c-3p in osteosarcoma contributes to cell proliferation via targeting ITGAV. *Cancer Biother Radiopharm*. 2016;31(5):153-158.
- Peng T, Zhou L, Qi H, et al. MiR-592 functions as a tumor suppressor in glioma by targeting IGF2BP2. *Tumour Biol*. 2017;39(7):1010428317719273.
- Li Z, Li B, Niu L, et al. miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9. *Oncol Rep*. 2017;37(1):297-304.
- Wang J, Tian X, Han R, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. *Oncogene*. 2014;33(9):1181-1189.
- Chen H, Ren C, Han C, et al. Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma. *PLoS One*. 2015;10(3):e0119384.
- Guo LM, Ding GF, Wu X, et al. MiR-135a-5p represses proliferation of HNSCC by targeting HOXA10. *Cancer Biol Ther*. 2018;19(11):973-983.
- Knyazev EN, Fomicheva KA, Mikhailenko DS, et al. Plasma levels of hsa-miR-619-5p and hsa-miR-1184 differ in prostatic benign hyperplasia and cancer. *Bull Exp Biol Med*. 2016;161(1):108-111.
- Liu T, Liu S, Xu Y, et al. Circular RNA-ZFR inhibited cell proliferation and promoted apoptosis in gastric cancer by sponging miR-130a/miR-107 and modulating PTEN. *Cancer Res Treat*. 2018;50(4):1396-1417.
- Hou W, Zhang H, Bai X, et al. Suppressive role of miR-592 in breast cancer by repressing TGF- $\beta$ 2. *Oncol Rep*. 2017;38(6):3447-3454.
- Zhou CH, Ye LP, Ye SX. Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival. *J Exp Clin Cancer Res*. 2012;31(1):18.
- Jiang SS, Fang WT, Hou YH. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. *Clin Cancer Res*. 2010;16(17):4363-4373.
- Capacchione KM, Hong X, Morgan KM. Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma. *Oncotarget*. 2014;5(11):3636-3650.

**How to cite this article:** Wang Y, Lu L-J, Duan Y, et al. Analysis of circular RNA expression profiles of lung cancer in Xuanwei, China. *J Clin Lab Anal*. 2020;34:e23521. <https://doi.org/10.1002/jcla.23521>